Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 22 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

42%

5 of 12 completed with results

Key Signals

5 with results100% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (2)
P 1 (4)
P 2 (10)

Trial Status

Completed12
Not Yet Recruiting5
Recruiting4
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 12 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT07678645Phase 2Not Yet Recruiting

The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching

NCT07646223Phase 2Not Yet Recruiting

Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis

NCT07607353Not ApplicableRecruitingPrimary

Biodegradable Stents in Primary Sclerosing Cholangitis

NCT07477782Phase 2Not Yet RecruitingPrimary

Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation

NCT07341282Phase 2Not Yet Recruiting

Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis

NCT06699121Phase 2RecruitingPrimary

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

NCT03333928Phase 2CompletedPrimary

A POC and Dose-Ranging Study of HTD1801 in PSC Patients

NCT03146936Recruiting

Swiss Primary Sclerosing Cholangitis Cohort Study

NCT01161992CompletedPrimary

Genomics of Primary Sclerosing Cholangitis (PSC)

NCT06975150Phase 2Not Yet RecruitingPrimary

Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis

NCT06026865Not ApplicableActive Not RecruitingPrimary

S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC)

NCT06767605Recruiting

Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai)

NCT06686810CompletedPrimary

Endoscopy and Primary Sclerosing Cholangitis

NCT06037577Phase 1Completed

Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

NCT03766035CompletedPrimary

Cholangioscopy in Primary Sclerosing Cholangitis (PSC)

NCT05082779Phase 1CompletedPrimary

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159

NCT02177136Phase 2CompletedPrimary

Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)

NCT02808312Phase 1Completed

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

NCT01672853Phase 2CompletedPrimary

Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)

NCT02061540Phase 2CompletedPrimary

Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis

Scroll to load more

Research Network

Activity Timeline